Theracos develops, acquires, and supports research programs in inflammation, metabolism, and depression through research activities throughout the world and establishes the clinical efficacy of its therapeutic candidates through multicenter international trials
Theracos does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Theracos will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 9/20/2013 | Series C | $327.39MM | $XXX.XX | $XXX.XX |
| 3/29/2011 | Series B | $123.09MM | $XXX.XX | $XXX.XX |
| 6/4/2002 | Series A | $11.08MM | $XXX.XX | $XXX.XX |
